vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and PARK AEROSPACE CORP (PKE). Click either name above to swap in a different company.

PARK AEROSPACE CORP is the larger business by last-quarter revenue ($17.3M vs $13.5M, roughly 1.3× Assertio Holdings, Inc.). On growth, PARK AEROSPACE CORP posted the faster year-over-year revenue change (20.3% vs -57.9%). Over the past eight quarters, PARK AEROSPACE CORP's revenue compounded faster (3.0% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

Park Electrochemical Corp, now called the Park Aerospace Corp, is a Melville, New York-based materials manufacturer for the telecommunications, Internet infrastructure, high-end computing, and aerospace industries. It produces high-technology digital and radio frequency(RF)/microwave printed circuit material products, composite materials. Its printed circuit materials are used for complex multilayer printed circuit boards and other electronic interconnection systems, such as multilayer back-p...

ASRT vs PKE — Head-to-Head

Bigger by revenue
PKE
PKE
1.3× larger
PKE
$17.3M
$13.5M
ASRT
Growing faster (revenue YoY)
PKE
PKE
+78.2% gap
PKE
20.3%
-57.9%
ASRT
Faster 2-yr revenue CAGR
PKE
PKE
Annualised
PKE
3.0%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ASRT
ASRT
PKE
PKE
Revenue
$13.5M
$17.3M
Net Profit
$3.0M
Gross Margin
34.1%
Operating Margin
-86.7%
21.0%
Net Margin
17.0%
Revenue YoY
-57.9%
20.3%
Net Profit YoY
87.1%
EPS (diluted)
$-4.54
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
PKE
PKE
Q4 25
$13.5M
$17.3M
Q3 25
$49.5M
$16.4M
Q2 25
$29.2M
$15.4M
Q1 25
$26.5M
$16.9M
Q4 24
$32.2M
$14.4M
Q3 24
$29.2M
$16.7M
Q2 24
$31.1M
$14.0M
Q1 24
$32.4M
$16.3M
Net Profit
ASRT
ASRT
PKE
PKE
Q4 25
$3.0M
Q3 25
$11.4M
$2.4M
Q2 25
$-16.4M
$2.1M
Q1 25
$-13.5M
$1.2M
Q4 24
$1.6M
Q3 24
$-2.9M
$2.1M
Q2 24
$-3.7M
$993.0K
Q1 24
$-4.5M
$2.7M
Gross Margin
ASRT
ASRT
PKE
PKE
Q4 25
34.1%
Q3 25
31.2%
Q2 25
30.6%
Q1 25
29.3%
Q4 24
26.6%
Q3 24
28.5%
Q2 24
29.3%
Q1 24
27.3%
Operating Margin
ASRT
ASRT
PKE
PKE
Q4 25
-86.7%
21.0%
Q3 25
23.2%
17.4%
Q2 25
-27.5%
15.7%
Q1 25
-50.0%
16.8%
Q4 24
-41.9%
12.8%
Q3 24
-10.4%
15.7%
Q2 24
-11.6%
14.9%
Q1 24
-13.4%
15.7%
Net Margin
ASRT
ASRT
PKE
PKE
Q4 25
17.0%
Q3 25
23.1%
14.7%
Q2 25
-56.0%
13.5%
Q1 25
-51.1%
7.4%
Q4 24
10.9%
Q3 24
-10.0%
12.4%
Q2 24
-11.8%
7.1%
Q1 24
-13.9%
16.3%
EPS (diluted)
ASRT
ASRT
PKE
PKE
Q4 25
$-4.54
$0.15
Q3 25
$0.11
$0.12
Q2 25
$-0.17
$0.10
Q1 25
$-0.14
$0.06
Q4 24
$-3.28
$0.08
Q3 24
$-0.03
$0.10
Q2 24
$-0.04
$0.05
Q1 24
$-0.05
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
PKE
PKE
Cash + ST InvestmentsLiquidity on hand
$63.4M
$63.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$94.0M
$106.6M
Total Assets
$267.0M
$118.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
PKE
PKE
Q4 25
$63.4M
$63.6M
Q3 25
$93.4M
$61.6M
Q2 25
$98.2M
$65.6M
Q1 25
$87.3M
$68.8M
Q4 24
$100.1M
$70.0M
Q3 24
$88.6M
$72.0M
Q2 24
$88.4M
$74.4M
Q1 24
$80.7M
$77.2M
Total Debt
ASRT
ASRT
PKE
PKE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
PKE
PKE
Q4 25
$94.0M
$106.6M
Q3 25
$105.8M
$105.8M
Q2 25
$93.3M
$105.0M
Q1 25
$108.5M
$107.2M
Q4 24
$121.1M
$107.4M
Q3 24
$130.5M
$110.3M
Q2 24
$132.2M
$111.7M
Q1 24
$134.5M
$112.9M
Total Assets
ASRT
ASRT
PKE
PKE
Q4 25
$267.0M
$118.1M
Q3 25
$319.8M
$116.4M
Q2 25
$273.8M
$120.7M
Q1 25
$286.4M
$122.1M
Q4 24
$284.7M
$124.2M
Q3 24
$276.0M
$125.1M
Q2 24
$279.4M
$129.4M
Q1 24
$282.0M
$132.3M
Debt / Equity
ASRT
ASRT
PKE
PKE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
PKE
PKE
Operating Cash FlowLast quarter
$-30.0M
$5.1M
Free Cash FlowOCF − Capex
$4.3M
FCF MarginFCF / Revenue
24.6%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
1.73×
TTM Free Cash FlowTrailing 4 quarters
$3.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
PKE
PKE
Q4 25
$-30.0M
$5.1M
Q3 25
$-4.8M
$-2.1M
Q2 25
$19.1M
$1.6M
Q1 25
$-12.5M
$969.0K
Q4 24
$11.5M
$2.7M
Q3 24
$-35.0K
$1.4M
Q2 24
$7.4M
$-423.0K
Q1 24
$7.5M
$5.3M
Free Cash Flow
ASRT
ASRT
PKE
PKE
Q4 25
$4.3M
Q3 25
$-2.3M
Q2 25
$1.1M
Q1 25
$338.0K
Q4 24
$2.7M
Q3 24
$1.3M
Q2 24
$-435.0K
Q1 24
$5.1M
FCF Margin
ASRT
ASRT
PKE
PKE
Q4 25
24.6%
Q3 25
-14.0%
Q2 25
7.2%
Q1 25
2.0%
Q4 24
18.6%
Q3 24
7.5%
Q2 24
-3.1%
Q1 24
31.4%
Capex Intensity
ASRT
ASRT
PKE
PKE
Q4 25
4.8%
Q3 25
1.1%
Q2 25
3.1%
Q1 25
3.7%
Q4 24
0.4%
Q3 24
0.0%
1.2%
Q2 24
0.1%
Q1 24
1.0%
Cash Conversion
ASRT
ASRT
PKE
PKE
Q4 25
1.73×
Q3 25
-0.42×
-0.88×
Q2 25
0.76×
Q1 25
0.78×
Q4 24
1.73×
Q3 24
0.70×
Q2 24
-0.43×
Q1 24
1.98×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

PKE
PKE

North America$16.8M97%
Other$546.0K3%

Related Comparisons